1.Predictive Factors of Methicillin-Resistant Staphylococcus aureus Infection in Elderly Patients with Community-Onset Pneumonia.
Hyeyoung JWA ; Jong Wook BEOM ; Jong Hoo LEE
Tuberculosis and Respiratory Diseases 2017;80(2):201-209
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infection is a severe and life-threatening disease in patients with community-onset (CO) pneumonia. However, the current guidelines lack specificity for a screening test for MRSA infection. METHODS: This study was retrospectively conducted in elderly patients aged ≥65 years, who had contracted CO-pneumonia during hospitalization at the Jeju National University Hospital, between January 2012 and December 2014. We analyzed the risk factors of MRSA in these patients and developed a scoring system to predict MRSA infection. RESULTS: A total of 762 patients were enrolled in this study, including 19 (2.4%) with MRSA infection. Healthcare-associated pneumonia (HCAP) showed more frequent MRSA infection compared to community-acquired pneumonia (4.4% vs. 1.5%, respectively; p=0.016). In a multivariate logistic regression analysis, admissions during the influenza season (odds ratio [OR], 2.896; 95% confidence interval [CI], 1.022–8.202; p=0.045), chronic kidney disease (OR, 3.555; 95% CI, 1.157–10.926; p=0.027), and intensive care unit admission (OR, 3.385; 95% CI, 1.035–11.075; p=0.044) were identified as predictive factors for MRSA infection. However, the presence of HCAP was not significantly associated with MRSA infection (OR, 1.991; 95% CI, 0.720–5.505; p=0.185). The scoring system consisted of three variables based on the multivariate analysis, and showed moderately accurate diagnostic prediction (area under curve, 0.790; 95% CI, 0.680–0.899; p<0.001). CONCLUSION: MRSA infection would be considered in elderly CO-pneumonia patients, with three risk factors identified herein. When managing elderly patients with pneumonia, clinicians might keep in mind that these risk factors are associated with MRSA infection, which may help in selecting appropriate antibiotics.
Aged*
;
Anti-Bacterial Agents
;
Community-Acquired Infections
;
Hospitalization
;
Humans
;
Influenza, Human
;
Intensive Care Units
;
Logistic Models
;
Mass Screening
;
Methicillin Resistance*
;
Methicillin-Resistant Staphylococcus aureus*
;
Mortality
;
Multivariate Analysis
;
Pneumonia*
;
Renal Insufficiency, Chronic
;
Retrospective Studies
;
Risk Factors
;
Seasons
;
Sensitivity and Specificity
2.Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.
Jonghoo LEE ; Ju Hee PARK ; Hyeyoung JWA ; Yee Hyung KIM
Yonsei Medical Journal 2017;58(4):778-785
PURPOSE: Peramivir is the first intravenously administered neuramidase inhibitor for immediate delivery of an effective single-dose treatment in patients with influenza. However, limited data are available on intravenous (IV) peramivir treatment compared to oral oseltamivir for these patients. MATERIALS AND METHODS: With a systematic review and meta-analysis, we compared the efficacy of IV peramivir with oral oseltamivir for treatment of patients with seasonal influenza. MEDLINE, EMBASE, and Cochrane Central Register were searched for relevant clinical trials. RESULTS: A total of seven trials [two randomized controlled trials (RCTs) and five non-randomized observational trials] involving 1676 patients were finally analyzed. The total number of peramivir- and oseltamivir-treated patients was 956 and 720, respectively. Overall, the time to alleviation of fever was lower in the peramivir-treated group compared with the oseltamivir-treated group [mean difference (MD), −7.17 hours; 95% confidence interval (CI) −11.00 to −3.34]. Especially, pooled analysis of observational studies (n=4) and studies of outpatients (n=4) demonstrated the superiority of the peramivir-treated group (MD, -7.83 hours; 95% CI −11.81 to −3.84 and MD, −7.71 hours; 95% CI −11.61 to −3.80, respectively). Mortality, length of hospital stay, change in virus titer 48 hours after admission, and the incidence of adverse events in these patients were not significantly different between the two groups. CONCLUSION: IV peramivir therapy might reduce the time to alleviation of fever in comparison with oral oseltamivir therapy in patients with influenza; however, we could not draw clear conclusions from a meta-analysis because of the few RCTs available and methodological limitations.
Fever
;
Humans
;
Incidence
;
Influenza, Human*
;
Length of Stay
;
Mortality
;
Oseltamivir*
;
Outpatients
;
Seasons
;
Viral Load
3.Iatrogenic pleural empyema caused by Propionibacterium acnes.
Hyeyoung JWA ; Jaechun LEE ; Gil Myeong SEONG ; Changhwan KIM
Allergy, Asthma & Respiratory Disease 2019;7(1):61-64
Propionibacterium acnes is one of the commensals living on the human skin and glands, implicated mainly in acnes, but seldom in deep infection. Pleural empyema is rarely complicated with closed thoracostomy. We experienced 1 case of empyema caused by P. acnes after pleural biopsy and closed thoracostomy through a percutaneous pigtail catheter. A 79-year-old man was admitted for cough, purulent sputum and shortness of breath. Three weeks ago, closed thoracostomy and pleural biopsy were performed to confirm a diagnosis for his recurrent pleural effusion. He had increased amount of right pleural effusion. Through the pigtail catheter, pleural effusion was removed. Gram-positive rods were observed in Gram stain, but not cultured. By 16S rRNA analysis, P. acnes was confirmed as the pathogen. His empyema was repeatedly treated with antibiotics, fibrolysis and irrigation. Pleural decortication was recommended. We report the first case of empyema with P. acnes in Korea, possibly complicated with closed thoracostomy procedures.
Aged
;
Anti-Bacterial Agents
;
Biopsy
;
Catheters
;
Cough
;
Diagnosis
;
Dyspnea
;
Empyema
;
Empyema, Pleural*
;
Gram-Positive Rods
;
Humans
;
Korea
;
Pleural Effusion
;
Propionibacterium acnes*
;
Propionibacterium*
;
Skin
;
Sputum
;
Thoracostomy
;
Thoracotomy
4.Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes.
Younghyup LIM ; Soyeon YOO ; Sang Ah LEE ; Sang Ouk CHIN ; Dahee HEO ; Jae Cheol MOON ; Shinhang MOON ; Kiyoung BOO ; Seong Taeg KIM ; Hye Mi SEO ; Hyeyoung JWA ; Gwanpyo KOH
Endocrinology and Metabolism 2015;30(2):208-215
BACKGROUND: Increased low density lipoprotein cholesterol (LDL-C) level and the presence of metabolic syndrome (MetS) are important risk factors for cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). Recent studies demonstrated apolipoprotein B (apoB), a protein mainly located in LDL-C, was an independent predictor of the development of CVD especially in patients with T2DM. The aim of this study was to investigate the relationship between apoB and MetS in T2DM patients. METHODS: We analyzed 912 patients with T2DM. Fasting blood samples were taken for glycated hemoglobin, high-sensitivity C-reactive protein, total cholesterol, triglyceride (TG), high density lipoprotein cholesterol, LDL-C, and apoB. MetS was defined by the modified National Cholesterol Education Program Adult Treatment Panel III criteria. We performed a hierarchical regression analysis with apoB as the dependent variable. Age, sex, the number of components of MetS and LDL-C were entered at model 1, the use of lipid-lowering medications at model 2, and the individual components of MetS were added at model 3. RESULTS: Seventy percent of total subjects had MetS. ApoB level was higher in subjects with than those without MetS (104.5+/-53.3 mg/dL vs. 87.7+/-33.7 mg/dL, P<0.01) even after adjusting for LDL-C. ApoB and LDL-C were positively correlated to the number of MetS components. The hierarchical regression analysis showed that the increasing number of MetS components was associated with higher level of apoB at step 1 and step 2 (beta=0.120, P<0.001 and beta=0.110, P<0.001, respectively). At step 3, TG (beta=0.116, P<0.001) and systolic blood pressure (beta=0.099, P<0.05) were found to significantly contribute to apoB. CONCLUSION: In patients with T2DM, apoB is significantly related to MetS independently of LDL-C level. Of the components of MetS, TG, and systolic blood pressure appeared to be determinants of apoB.
Adult
;
Apolipoproteins B
;
Apolipoproteins*
;
Blood Pressure
;
C-Reactive Protein
;
Cardiovascular Diseases
;
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL*
;
Diabetes Mellitus, Type 2
;
Education
;
Fasting
;
Hemoglobin A, Glycosylated
;
Humans
;
Risk Factors
;
Triglycerides
5.Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?.
Byung Cheol SONG ; Yoo Kyung CHO ; Hyeyoung JWA ; Eun Kwang CHOI ; Heung Up KIM ; Hyun Joo SONG ; Soo Young NA ; Sun Jin BOO ; Seung Uk JEONG
Clinical and Molecular Hepatology 2014;20(4):355-360
BACKGROUND/AIMS: Spontaneous HBeAg seroconversion occurs frequently in the immune reactive phase in HBeAg-positive chronic hepatitis B (CHB). Therefore, observation for 3-6 months before commencing antiviral therapy is recommended in patients with alanine aminotransferase (ALT) levels that exceed twice the upper limit of normal (ULN). However, HBeAg seroconversion occurs infrequently in patients infected with hepatitis B virus (HBV) genotype C. The aim of the present study was to determine whether the waiting policy is necessary in endemic areas of HBV genotype C infection. METHODS: Ninety patients with HBeAg-positive CHB were followed prospectively without administering antiviral therapy for 6 months. Antiviral therapy was initiated promptly at any time if there was any evidence of biochemical (i.e., acute exacerbation of HBV infection or aggravation of jaundice) or symptomatic deterioration. After 6 months of observation, antiviral therapy was initiated according to the patient's ALT and HBV DNA levels. RESULTS: Only one patient (1.1%) achieved spontaneous HBeAg seroconversion. Biochemical and symptomatic deterioration occurred before 6 months in 17 patients (18.9%) and 5 patients, respectively. High ALT and HBV DNA levels were both independent risk factors for biochemical deterioration. Of 15 patients with HBV DNA > or =5.1x107 IU/mL and ALT > or =5xULN, biochemical deterioration occurred in 7 (46.7%), including 1 patient receiving liver transplantation due to liver failure. CONCLUSIONS: Spontaneous HBeAg seroconversion in patients with HBeAg-positive CHB is rare within 6 months. Biochemical deterioration was common and may lead to liver failure. Immediate antiviral therapy should be considered, especially in patients with high ALT and HBV DNA levels in endemic areas of genotype C infection.
Adult
;
Alanine Transaminase/blood
;
Antiviral Agents/*therapeutic use
;
DNA, Viral/blood
;
Female
;
Follow-Up Studies
;
Genotype
;
Guanine/analogs & derivatives/therapeutic use
;
Hepatitis B e Antigens/*blood
;
Hepatitis B virus/*genetics
;
Hepatitis B, Chronic/*drug therapy
;
Humans
;
Male
;
Middle Aged
;
Prospective Studies
;
Risk Factors
6.A Case of Posterior Mediastinal Plasmacytoma Confounded by Community-Acquired Pneumonia.
Dahee HEO ; Ki Yung BOO ; Hyeyoung JWA ; Hwa Young LEE ; Jihyun KIM ; Seong Taeg KIM ; Hye Mi SEO ; Sang Hoon HAN ; Young Hee MAENG ; Jong Hoo LEE
Tuberculosis and Respiratory Diseases 2015;78(3):262-266
Plasmacytomas are extramedullary accumulations of plasma cells originating from soft tissue. Mediastinal plasmacytoma is a rare presentation. A 67-year-old man recovered after antibiotic treatment for community-acquired pneumonia. However, on convalescent chest radiography after 3 months, mass like lesion at the right lower lung field was newly detected. Follow-up chest computed tomography (CT) revealed an increase in the extent of the right posterior mediastinal mass that we had considered to be pneumonic consolidations on previous CT scans. Through percutaneous needle biopsy, we diagnosed IgG kappa type extramedullary plasmacytoma of the posterior mediastinum.
Aged
;
Biopsy, Needle
;
Diagnosis
;
Follow-Up Studies
;
Hematopoiesis, Extramedullary
;
Humans
;
Immunoglobulin G
;
Lung
;
Mediastinum
;
Plasma Cells
;
Plasmacytoma*
;
Pneumonia*
;
Radiography
;
Thorax
;
Tomography, X-Ray Computed